EXHIBIT 99.1
JOINT FILER AGREEMENT
In accordance with Rule13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that a single Schedule 13D, or any amendment thereto, relating to the equity securities of CASI Pharmaceuticals, Inc., a Delaware corporation, shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as Exhibit 99.1 to such Schedule 13D.
Dated: May 14, 2018 | SPECTRUM PHARMACEUTICALS, INC., | |||||||||||
a Delaware corporation | ||||||||||||
| By: | /s/ Kurt A. Gustafson | |||||||||||
| Name: | Kurt A. Gustafson | |||||||||||
| Title: | Executive Vice President and Chief Financial Officer | |||||||||||
| Dated: May 14, 2018 | SPECTRUM PHARMACEUTICALS CAYMAN, L.P., | |||||||||||
| an Exempted Limited Partnership organized under the laws of the Cayman Islands | ||||||||||||
| By: | Spectrum Pharmaceuticals International Holdings, LLC | |||||||||||
| Its: | General Partner | |||||||||||
| By: | Spectrum Pharmaceuticals, Inc. | |||||||||||
| Its: | Managing Member | |||||||||||
| By: | /s/ Kurt A. Gustafson | |||||||||||
| Name: | Kurt A. Gustafson | |||||||||||
| Title: | Executive Vice President and Chief Financial Officer | |||||||||||
